EGFR and adenocarcinoma: Among the co-occurring mutations in EGFR-mutated adenocarcinoma, TP53 mutations were the most frequently observed (16.2%), followed by CTNNB1 mutations (4.6%) and PIK3CA mutations (4.6%).